SHIFT AI Newsroom · GLOBAL
Incretin Therapies in Obesity-related HFpEF: Clinical Trial Update
A clinical trial on incretin therapies for obesity-related heart failure with preserved ejection fraction (HFpEF) has been registered on ClinicalTrials.gov.
A clinical trial on incretin therapies for obesity-related heart failure with preserved ejection fraction (HFpEF) has been registered on ClinicalTrials.gov. The trial aims to investigate the efficacy of incretin therapies in patients with this condition. While the results of this trial are awaited, it is essential to note that the safety and efficacy of incretin therapies in patients with obesity-related HFpEF are currently unknown.
What this means in the UK
This trial may provide insights into the potential benefits of incretin therapies for UK patients with obesity-related HFpEF, a condition with limited treatment options.
Known facts
- A clinical trial on incretin therapies for obesity-related HFpEF has been registered on ClinicalTrials.gov.